Watanabe Todd Franklin's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 3, 2026
- Accession no.
- 0001628280-26-014327
- Filed
- Mar 3, 2026
- Trade date
- Feb 27-Mar 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $940.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watanabe Todd FranklinCIK 0001801061 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +102,000 | $0.00 | $0 | 823,306 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −36,281 | $25.16 | −$912,829.96 | 787,025 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −1,068 | $25.91 | −$27,671.88 | 785,957 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +266,000 | $0.00 | $0 | 266,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.